Trevogrumab Preserves Muscle Mass During GLP-1 Agonist Weight Loss in Phase 2 Trial

Results from the Phase 2 COURAGE trial indicate that trevogrumab, an anti-myostatin antibody, can preserve lean mass and muscle during weight loss induced by GLP-1 receptor agonists in people with obesity. Presented at the EASD Annual Meeting and in press with The Lancet, these findings suggest a potential new approach to obesity care by mitigating muscle loss, a common concern with significant weight reduction.